Generic name |
pantoprazole sodium | |
---|---|---|
Strength |
40 mg |
|
Form |
tablet |
Criteria |
Approval period |
---|---|
1. For gastroesophageal reflux disease (GERD), reflux esophagitis, duodenal ulcer, or gastric ulcer |
Indefinite |
OR |
|
2. For Barrett's esophagus, Zollinger-Ellison syndrome, connective tissue disease, e.g., lupus, scleroderma, CREST |
Indefinite |
OR |
|
3. For eradication of Helicobacter pylori as part of triple therapy |
14 days |
PLUS | |
Failure of reasonable trials of, or intolerance to, rabeprazole AND pantoprazole magnesium |
CREST is an acronym for the five main features of the limited form of scleroderma: calcinosis, Raynaud’s disease, esophageal dysmotility, sclerodactyly, and telangiectasia.
A reasonable trial of rabeprazole and pantoprazole magnesium is considered a trial at usual adult doses for at least 4 weeks each of rabeprazole and pantoprazole magnesium.